PB2022: EXPLORING ALTERNATIVE DOSING REGIMENS OF SINGLE-AGENT BELANTAMAB MAFODOTIN ON SAFETY AND EFFICACY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DREAMM-14

por Hultcrantz, M., Kleinman, D., Ghataorhe, P., Mckeown, A., He, W., Ling, T., Jewell, R. C., Byrne, J., Eliason, L., Scott, E., Opalinska, J.
Publicado 2022

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022